Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
Hypertension 58(5):784790 Spit KA, Muskiet MHA, Tonneijck L, Smits MM, Kramer MHH, Joles JA et al (2019) Renal sinus fat and renal hemodynamics: a cross-sectional analysis
To view or add a comment, sign in --$. - Novo Nordisk is aggressively building its rare disease arsenal beyond diabetes and obesity: They gain exclusive global rights to zaltenibart (formerly OMS906, an investigational MASP-3 inhibitor for complement-mediated blood and kidney disorders), which was in Phase 3 preparation for paroxysmal nocturnal hemoglobinuria (PNH) before Omeros paused the program due to capital constraints
Even today after significant efforts to develop pharmaceutical strategies to mitigate muscle wasting (Sepulveda et al., 2015), contractile activity in the form of resistance exercise (RE) remains the most efficacious intervention
The $58B Weight Loss Drug Market in One Chart The $58B Weight Loss Drug Market in One Chart Weight loss drugs have surged in popularity in recent years, transforming the pharmaceutical landscape
[DOI] [PubMed] [Google Scholar] 8.Tan D.J.H., Setiawan V.W., Ng C.H., Lim W.H., Muthiah M.D., Tan E.X., Dan Y.Y., Roberts L.R., Loomba R., Huang D.Q
